메뉴 건너뛰기




Volumn 20, Issue 41, 2014, Pages 15110-15118

S-1 in the treatment of pancreatic cancer

Author keywords

Adjuvant therapy; Chemoradiotherapy; Chemotherapy; Pancreatic cancer; Randomized controlled trial; S 1

Indexed keywords

ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

EID: 84912103359     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i41.15110     Document Type: Review
Times cited : (42)

References (73)
  • 2
    • 77955635233 scopus 로고    scopus 로고
    • Cancer statistics, 2010
    • PMID: 20610543
    • Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]
    • (2010) CA Cancer J Clin , vol.60 , pp. 277-300
    • Jemal, A.1    Siegel, R.2    Xu, J.3    Ward, E.4
  • 3
    • 0029835349 scopus 로고    scopus 로고
    • Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
    • [PMID: 8862723]
    • Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557 [PMID: 8862723]
    • (1996) Anticancer Drugs , vol.7 , pp. 548-557
    • Shirasaka, T.1    Shimamato, Y.2    Ohshimo, H.3    Yamaguchi, M.4    Kato, T.5    Yonekura, K.6    Fukushima, M.7
  • 4
    • 0023250474 scopus 로고
    • Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts
    • [PMID: 3114201]
    • Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748-755 [PMID: 3114201]
    • (1987) Jpn J Cancer Res , vol.78 , pp. 748-755
    • Tatsumi, K.1    Fukushima, M.2    Shirasaka, T.3    Fujii, S.4
  • 5
    • 0027227591 scopus 로고
    • Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
    • [PMID: 7689420]
    • Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-4009 [PMID: 7689420]
    • (1993) Cancer Res , vol.53 , pp. 4004-4009
    • Shirasaka, T.1    Shimamoto, Y.2    Fukushima, M.3
  • 6
    • 71249128928 scopus 로고    scopus 로고
    • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study
    • PMID: 19818685
    • Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069 [PMID: 19818685 DOI: 10.1016/S1470-2045(09)70259-1]
    • (2009) Lancet Oncol , vol.10 , pp. 1063-1069
    • Boku, N.1    Yamamoto, S.2    Fukuda, H.3    Shirao, K.4    Doi, T.5    Sawaki, A.6    Koizumi, W.7    Saito, H.8    Yamaguchi, K.9    Takiuchi, H.10    Nasu, J.11    Ohtsu, A.12
  • 16
    • 23844431643 scopus 로고    scopus 로고
    • An early phase II study of S-1 in patients with metastatic pancreatic cancer
    • [PMID: 16006754]
    • Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005; 68: 171-178 [PMID: 16006754]
    • (2005) Oncology , vol.68 , pp. 171-178
    • Ueno, H.1    Okusaka, T.2    Ikeda, M.3    Takezako, Y.4    Morizane, C.5
  • 18
    • 0034327360 scopus 로고    scopus 로고
    • Equilibrative- sensitive nucleoside transporter and its role in gemcitabine sensitivity
    • [PMID: 11085530]
    • Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative- sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000; 60: 6075-6079 [PMID: 11085530]
    • (2000) Cancer Res , vol.60 , pp. 6075-6079
    • Rauchwerger, D.R.1    Firby, P.S.2    Hedley, D.W.3    Moore, M.J.4
  • 19
    • 33745258389 scopus 로고    scopus 로고
    • Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
    • [PMID: 16721372]
    • Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94: 1575-1579 [PMID: 16721372]
    • (2006) Br J Cancer , vol.94 , pp. 1575-1579
    • Nakamura, K.1    Yamaguchi, T.2    Ishihara, T.3    Sudo, K.4    Kato, H.5    Saisho, H.6
  • 21
  • 22
    • 68149117513 scopus 로고    scopus 로고
    • Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer
    • PMID: 19151975
    • Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 64: 707-713 [PMID: 19151975 DOI: 10.1007/s00280-008-0918-0]
    • (2009) Cancer Chemother Pharmacol , vol.64 , pp. 707-713
    • Lee, G.W.1    Kim, H.J.2    Ju, J.H.3    Kim, S.H.4    Kim, H.G.5    Kim, T.H.6    Kim, H.J.7    Jeong, C.Y.8    Kang, J.H.9
  • 23
    • 58149389383 scopus 로고    scopus 로고
    • S-1 and gemcitabine as an outpatient- based regimen in patients with advanced or metastatic pancreatic cancer
    • PMID: 19060295
    • Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS. S-1 and gemcitabine as an outpatient- based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol 2009; 39: 49-53 [PMID: 19060295 DOI: 10.1093/jjco/hyn126]
    • (2009) Jpn J Clin Oncol , vol.39 , pp. 49-53
    • Kim, M.K.1    Lee, K.H.2    Jang, B.I.3    Kim, T.N.4    Eun, J.R.5    Bae, S.H.6    Ryoo, H.M.7    Lee, S.A.8    Hyun, M.S.9
  • 27
    • 0036682041 scopus 로고    scopus 로고
    • Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
    • [PMID: 12149301]
    • Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275 [PMID: 12149301]
    • (2002) J Clin Oncol , vol.20 , pp. 3270-3275
    • Berlin, J.D.1    Catalano, P.2    Thomas, J.P.3    Kugler, J.W.4    Haller, D.G.5    Benson, A.B.6
  • 30
    • 84867072111 scopus 로고    scopus 로고
    • Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer
    • abstr 311
    • Ku GY, Haaland B, Ioka T, Isayama H, Nakai Y, Cheng AL, Okusaka T, de Lima Lopes G. Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer. J Clin Oncol 2012; 30 (suppl): abstr 311
    • (2012) J Clin Oncol , vol.30
    • Ku, G.Y.1    Haaland, B.2    Ioka, T.3    Isayama, H.4    Nakai, Y.5    Cheng, A.L.6    Okusaka, T.7    De Lima Lopes, G.8
  • 31
    • 84912069926 scopus 로고    scopus 로고
    • Efficacy and safety of Gemcitabine plus S-1 treatment in locally advanced and metastatic pancreatic cancer: A pooled analysis of three randomized trials using updated individual patient data
    • abstract 2595
    • Ishii H, Okusaka T, Ikari T, Isayama H, Furuse J, Nakai Y, Imai S, Okamura S, Hamada C. Efficacy and safety of Gemcitabine plus S-1 treatment in locally advanced and metastatic pancreatic cancer: A pooled analysis of three randomized trials using updated individual patient data. ECCO 2013; abstract 2595
    • (2013) ECCO
    • Ishii, H.1    Okusaka, T.2    Ikari, T.3    Isayama, H.4    Furuse, J.5    Nakai, Y.6    Imai, S.7    Okamura, S.8    Hamada, C.9
  • 32
    • 79960019683 scopus 로고    scopus 로고
    • Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
    • PMID: 21565490
    • Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-1681 [PMID: 21565490 DOI: 10.1016/j.ejca.2011.04.011]
    • (2011) Eur J Cancer , vol.47 , pp. 1676-1681
    • Pelzer, U.1    Schwaner, I.2    Stieler, J.3    Adler, M.4    Seraphin, J.5    Dörken, B.6    Riess, H.7    Oettle, H.8
  • 33
    • 48949087810 scopus 로고    scopus 로고
    • A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
    • abstr 4508
    • Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26 (suppl): abstr 4508
    • (2008) J Clin Oncol , vol.26
    • Pelzer, U.1    Schwaner, I.2    Stieler, J.3    Adler, M.4    Seraphin, J.5    Dörken, B.6    Riess, H.7    Oettle, H.8
  • 35
    • 79953804276 scopus 로고    scopus 로고
    • Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
    • PMID: 20352216
    • Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011; 67: 249-254 [PMID: 20352216 DOI: 10.1007/s00280-010-1311-3]
    • (2011) Cancer Chemother Pharmacol , vol.67 , pp. 249-254
    • Sudo, K.1    Yamaguchi, T.2    Nakamura, K.3    Denda, T.4    Hara, T.5    Ishihara, T.6    Yokosuka, O.7
  • 38
    • 84912069731 scopus 로고    scopus 로고
    • A randomized phase II study of S-1 plus leucovorin versus S-1 alone in patients with Gemcitabine-refractory pancreatic cancer
    • abstract 406
    • Okusaka T, Ueno M, Omuro Y, Isayama H, Fukutomi A, Ikeda M, Mizuno M, Fukuzawa K, Hyodo I, Boku N. A randomized phase II study of S-1 plus leucovorin versus S-1 alone in patients with Gemcitabine-refractory pancreatic cancer. ESMO 2013; abstract 406
    • (2013) ESMO
    • Okusaka, T.1    Ueno, M.2    Omuro, Y.3    Isayama, H.4    Fukutomi, A.5    Ikeda, M.6    Mizuno, M.7    Fukuzawa, K.8    Hyodo, I.9    Boku, N.10
  • 39
    • 0036569654 scopus 로고    scopus 로고
    • Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer
    • [PMID: 12007953]
    • Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002; 53: 146-150 [PMID: 12007953]
    • (2002) Int J Radiat Oncol Biol Phys , vol.53 , pp. 146-150
    • Shinchi, H.1    Takao, S.2    Noma, H.3    Matsuo, Y.4    Mataki, Y.5    Mori, S.6    Aikou, T.7
  • 40
    • 2942648695 scopus 로고    scopus 로고
    • Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy
    • [PMID: 15169811]
    • Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214-2232 [PMID: 15169811]
    • (2004) J Clin Oncol , vol.22 , pp. 2214-2232
    • Rich, T.A.1    Shepard, R.C.2    Mosley, S.T.3
  • 42
    • 0030938059 scopus 로고    scopus 로고
    • Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma
    • [PMID: 9118032]
    • Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997; 79: 1516-1520 [PMID: 9118032]
    • (1997) Cancer , vol.79 , pp. 1516-1520
    • Ishii, H.1    Okada, S.2    Tokuuye, K.3    Nose, H.4    Okusaka, T.5    Yoshimori, M.6    Nagahama, H.7    Sumi, M.8    Kagami, Y.9    Ikeda, H.10
  • 43
    • 78149320175 scopus 로고    scopus 로고
    • Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo
    • [PMID: 20878125]
    • Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H, Sakata Y. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 2010; 24: 1307-1313 [PMID: 20878125]
    • (2010) Oncol Rep , vol.24 , pp. 1307-1313
    • Fukushima, M.1    Sakamoto, K.2    Sakata, M.3    Nakagawa, F.4    Saito, H.5    Sakata, Y.6
  • 46
    • 34247617372 scopus 로고    scopus 로고
    • Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer
    • [PMID: 17437021]
    • Shinchi H, Maemura K, Noma H, Mataki Y, Aikou T, Takao S. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer 2007; 96: 1353-1357 [PMID: 17437021]
    • (2007) Br J Cancer , vol.96 , pp. 1353-1357
    • Shinchi, H.1    Maemura, K.2    Noma, H.3    Mataki, Y.4    Aikou, T.5    Takao, S.6
  • 49
    • 84857039587 scopus 로고    scopus 로고
    • A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer
    • PMID: 21647560
    • Shinchi H, Maemura K, Mataki Y, Kurahara H, Sakoda M, Ueno S, Hiraki Y, Nakajo M, Natsugoe S, Takao S. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 2012; 19: 152-158 [PMID: 21647560 DOI: 10.1007/s00534-011-0400-y]
    • (2012) J Hepatobiliary Pancreat Sci , vol.19 , pp. 152-158
    • Shinchi, H.1    Maemura, K.2    Mataki, Y.3    Kurahara, H.4    Sakoda, M.5    Ueno, S.6    Hiraki, Y.7    Nakajo, M.8    Natsugoe, S.9    Takao, S.10
  • 50
    • 58249132914 scopus 로고    scopus 로고
    • Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer
    • PMID: 18828020
    • Kim HM, Bang S, Park JY, Seong J, Song SY, Chung JB, Park SW. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 535-541 [PMID: 18828020 DOI: 10.1007/s00280-008-0836-1]
    • (2009) Cancer Chemother Pharmacol , vol.63 , pp. 535-541
    • Kim, H.M.1    Bang, S.2    Park, J.Y.3    Seong, J.4    Song, S.Y.5    Chung, J.B.6    Park, S.W.7
  • 51
    • 35748929435 scopus 로고    scopus 로고
    • Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Up-regulation of thymidine phosphorylase
    • [PMID: 17762760]
    • Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 2007; 13: 247-256 [PMID: 17762760]
    • (2007) Cancer J , vol.13 , pp. 247-256
    • Saif, M.W.1    Black, G.2    Roy, S.3    Bell, D.4    Russo, S.5    Eloubeidi, M.A.6    Steg, A.7    Johnson, M.R.8    Zelterman, D.9    Diasio, R.B.10
  • 52
    • 80051613675 scopus 로고    scopus 로고
    • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
    • PMID: 21709185
    • Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29: 3037-3043 [PMID: 21709185 DOI: 10.1200/JCO.2010.33.8038]
    • (2011) J Clin Oncol , vol.29 , pp. 3037-3043
    • Crane, C.H.1    Varadhachary, G.R.2    Yordy, J.S.3    Staerkel, G.A.4    Javle, M.M.5    Safran, H.6    Haque, W.7    Hobbs, B.D.8    Krishnan, S.9    Fleming, J.B.10    Das, P.11    Lee, J.E.12    Abbruzzese, J.L.13    Wolff, R.A.14
  • 53
    • 0032127244 scopus 로고    scopus 로고
    • Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
    • [PMID: 9849491]
    • Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281 [PMID: 9849491]
    • (1998) Eur J Cancer , vol.34 , pp. 1274-1281
    • Miwa, M.1    Ura, M.2    Nishida, M.3    Sawada, N.4    Ishikawa, T.5    Mori, K.6    Shimma, N.7    Umeda, I.8    Ishitsuka, H.9
  • 58
    • 70249099504 scopus 로고    scopus 로고
    • A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
    • PMID: 19690548
    • Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908-915 [PMID: 19690548 DOI: 10.1038/sj.bjc.6605256]
    • (2009) Br J Cancer , vol.101 , pp. 908-915
    • Ueno, H.1    Kosuge, T.2    Matsuyama, Y.3    Yamamoto, J.4    Nakao, A.5    Egawa, S.6    Doi, R.7    Monden, M.8    Hatori, T.9    Tanaka, M.10    Shimada, M.11    Kanemitsu, K.12
  • 60
    • 57849151618 scopus 로고    scopus 로고
    • The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: An in vivo study
    • [PMID: 19180995]
    • Eguchi T, Kodera Y, Nakanishi H, Yokoyama H, Ohashi N, Ito Y, Nakayama G, Koike M, Fujiwara M, Nakao A. The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo 2008; 22: 707-712 [PMID: 19180995]
    • (2008) Vivo , vol.22 , pp. 707-712
    • Eguchi, T.1    Kodera, Y.2    Nakanishi, H.3    Yokoyama, H.4    Ohashi, N.5    Ito, Y.6    Nakayama, G.7    Koike, M.8    Fujiwara, M.9    Nakao, A.10
  • 61
    • 31544483098 scopus 로고    scopus 로고
    • Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent proteintagged human gastric cancer cell line
    • [PMID: 16428473]
    • Yokoyama H, Nakanishi H, Kodera Y, Ikehara Y, Ohashi N, Ito Y, Koike M, Fujiwara M, Tatematsu M, Nakao A. Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent proteintagged human gastric cancer cell line. Clin Cancer Res 2006; 12: 361-368 [PMID: 16428473]
    • (2006) Clin Cancer Res , vol.12 , pp. 361-368
    • Yokoyama, H.1    Nakanishi, H.2    Kodera, Y.3    Ikehara, Y.4    Ohashi, N.5    Ito, Y.6    Koike, M.7    Fujiwara, M.8    Tatematsu, M.9    Nakao, A.10
  • 63
    • 77951709577 scopus 로고    scopus 로고
    • Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages
    • PMID: 20422030
    • Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267 [PMID: 20422030 DOI: 10.1371/journal.pmed.1000267]
    • (2010) PLoS Med , vol.7
    • Gillen, S.1    Schuster, T.2    Meyer Zum Büschenfelde, C.3    Friess, H.4    Kleeff, J.5
  • 65
    • 34250816847 scopus 로고    scopus 로고
    • A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
    • [PMID: 17453298]
    • Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14: 2088-2096 [PMID: 17453298]
    • (2007) Ann Surg Oncol , vol.14 , pp. 2088-2096
    • Palmer, D.H.1    Stocken, D.D.2    Hewitt, H.3    Markham, C.E.4    Hassan, A.B.5    Johnson, P.J.6    Buckels, J.A.7    Bramhall, S.R.8
  • 66
    • 80255122607 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer
    • PMID: 21913045
    • Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011; 15: 2059-2069 [PMID: 21913045 DOI: 10.1007/s11605-011-1659-7]
    • (2011) J Gastrointest Surg , vol.15 , pp. 2059-2069
    • Laurence, J.M.1    Tran, P.D.2    Morarji, K.3    Eslick, G.D.4    Lam, V.W.5    Sandroussi, C.6
  • 68
    • 0029996291 scopus 로고    scopus 로고
    • Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations
    • [PMID: 9173680]
    • Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996; 26: 395-403 [PMID: 9173680]
    • (1996) Xenobiotica , vol.26 , pp. 395-403
    • Shimada, T.1    Yamazaki, H.2    Guengerich, F.P.3
  • 69
    • 0033739717 scopus 로고    scopus 로고
    • Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro
    • [PMID: 11106261]
    • Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000; 6: 4409-4415 [PMID: 11106261]
    • (2000) Clin Cancer Res , vol.6 , pp. 4409-4415
    • Ikeda, K.1    Yoshisue, K.2    Matsushima, E.3    Nagayama, S.4    Kobayashi, K.5    Tyson, C.A.6    Chiba, K.7    Kawaguchi, Y.8
  • 73
    • 84872736743 scopus 로고    scopus 로고
    • Impact of the gene expressions of thymidylate synthase and dihydropyrimidine dehydrogenase on survival in patients enrolled in the ACTS-GC study
    • abstr 52
    • Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H. Impact of the gene expressions of thymidylate synthase and dihydropyrimidine dehydrogenase on survival in patients enrolled in the ACTS-GC study. J Clin Oncol 2012; 30 (suppl 4): abstr 52
    • (2012) J Clin Oncol , vol.30
    • Sasako, M.1    Terashima, M.2    Ichikawa, W.3    Ochiai, A.4    Kitada, K.5    Kurahashi, I.6    Sakuramoto, S.7    Katai, H.8    Sano, T.9    Imamura, H.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.